Synthetic control arms (SCAs) can help improve clinical trial effectiveness, especially for rare diseases with low participant numbers, or for conditions where the use of a placebo or comparator therapy may be considered unethical. SCAs reduce time and cost of clinical trials and can enhance the effectiveness of single arm trials.
SENSIGHT’s proprietary tools can be used to define patient cohorts by multiple criteria and build control arms in the platform, helping users to:
Using SENSIGHT’s proprietary deep clustering tools, patient stratification analyses can support the identification of sub-phenotypes within a patient cohort, and support the development of clinical decision trees that will provide additional insights and enhance clinical trials planning.
SENSIGHT offers an added level of data analysis sophistication with AI interpretation of radiology reports, providing a deeper level of insight into pathology including patient stratification, patient progression analysis and outcome prediction.